未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFruquintinib联合紫杉醇与安慰剂联合紫杉醇治疗胃或胃食管交界处腺癌的比较: FRUTIGA随机3期试验
Wang, Feng; Shen, Lin; Guo, Weijian; Liu, Tianshu; Li, Jin; Qin, Shukui; Bai, Yuxian; Chen, Zhendong; Wang, Jufeng; Pan, Yueyin; Shu, Yongqian; Zhao, Fuyou; Cheng, Ying; Ye, Feng; Gu, Kangsheng; Zhang, Tao; Pan, Hongming; Zhong, Haijun; Zhou, Fuxiang; Qin, Yanru; Yang, Lei; Mao, Weidong; Li, Qiu; Dai, Wenxiang; Li, Wei; Wang, Shubin; Tang, Yong; Ma, Dong; Yin, Xianli; Deng, Yanhong; Yuan, Ying; Li, Man; Hu, Wenwei; Chen, Donghui; Li, Guoxin; Liu, Qiqi; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Xu, Rui-Hua 分享 收藏 分享 收藏 Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studyZhang, Bo; Song, Yan; Luo, Suxia; Yin, Xianli; Li, Enxiao; Wang, Hui; He, Yifu; Liu, Zhihui; Fan, Qingxia; Liang, Xinjun; Shu, Yongqian; Liu, Yunpeng; Xu, Nong; Zhang, Shu; Zhuang, Zhixiang; Zhang, Jingdong; Kou, Xiaoge; Wang, Fen; Zhu, Xiaodong; Zeng, Shan; Wang, Ke; Zhong, Haijun; Li, Shengmian; Bai, Yuxian; Yu, Junyan; Dou, Yiwei; Ma, Taiyang; Liu, Qian; Huang, Jing 分享 收藏 First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis晚期胃，胃食管交界处和食管腺癌患者的一线nivolumab加化疗与化疗: CheckMate 649中国亚组分析Liu, Tianshu; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, Lin 分享 收藏 Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trialQin, Shukui; Li, Jin; Zhong, Haijun; Jin, Chuan; Chen, Lili; Yuan, Xianglin; Fan, Qingxia; Chen, Kehe; Cao, Peiguo; Xiao, Jianjun; Jiang, Da; Zhang, Tao; Zhang, Hongyu; Wang, Xicheng; Wang, Wei; Han, Lin; Wang, Qingyu; Zhu, Jun 分享 收藏 A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinomaHuang, J.; Luo, S.; Chen, P.; Pan, Y.; Zhuang, Z.; Liu, B.; Ling, Y.; Zhang, J.; Fan, Q.; Wang, H.; Lin, R.; Zhong, H.; Chen, Z.; Li, S.; Lv, J.; Cao, B.; Zhao, L.; Yang, Y.; Tong, J.; Cang, S. 分享 收藏 A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRCZhang, D.; Bai, C.; Zhang, J.; Zhang, Y.; Liu, T.; Pan, H.; Zhong, H.; Lin, X.; Qiu, W-S.; Liu, Y.; Yuan, X.; Zhang, T.; Yin, X.; Deng, Y.; Hu, X.; Xu, R. 分享 收藏 分享 收藏 Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III StudyQin, Shukui; Li, Jin; Bai, Yuxian; Shu, Yongqian; Li, Wei; Yin, Xianli; Cheng, Ying; Sun, Guoping; Deng, Yanhong; Zhong, Haijun; Li, Yunfeng; Qian, Xiaoping; Zhang, Liangming; Zhang, Jingdong; Chen, Kehe; Kang, Wenying 分享 收藏 Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in FRESCO trialFRESCO试验中接受fruquintinib治疗的转移性结直肠癌患者的质量调整生存Qin, Shukui; Li, Jin; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Rui-Hua; Zhong, Haijun; Chen, Zhendong; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Xu, Jianming; Peng, Cike; Chen, Yun; Li, Hongyan; Wang, Ning; Guo, Xiaojun; Peng, Mengye; Fan, Songhua; Shen, Lin 分享 收藏 Endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest and apoptosis through down-regulation of the phosphatidylinositide 3-kinase/Akt/HDM2 pathway (Withdrawal of Vol 284, Pg 24773, 2009)Ma, Shenglin; Yang, Yunshan; Wang, Chunmei; Hui, Ning; Gu, Linhui; Zhong, Haijun; Cai, Zhijian; Wang, Qingqing; Zhang, Qinghua; Li, Nan; Cao, Xuetao 分享 收藏 Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trialFRESCO中先前抗VEGF或抗EGFR靶向治疗的亚组分析，一项随机，双盲，III期试验Xu, Ruihua; Qin, Shukui; Guo, Weijian; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Xu, Jianming; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Li, Jian; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Wang, Ning; Zhang, Bin; Han, Rubing; Su, Weiguo; Guo, Xiaojun; Li, Jin 分享 收藏 Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III studyQin, S.; Li, J.; Bai, Y.; Shu, Y.; Li, W.; Yin, X.; Cheng, Y.; Sun, G.; Deng, Y.; Zhong, H.; Li, Y.; Qian, X.; Zhang, L.; Zhang, J.; Chen, K.; Zhang, L.; Li, W.; Jiang, W.; Liu, S.; Chai, K. 分享 收藏 Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial中国既往接受过治疗的转移性结直肠癌患者使用Fruquintinib的安全性和不良事件: FRESCO 3期临床试验分析Li, Jin; Guo, Weijian; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Chen, Zhendong; Zhong, Haijun; Xu, Ruihua; Pan, Hongming; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Xu, Jianming; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Shen, Lin; Chen, Haihui; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Guo, Xiaojun; Wang, Ning; Han, Rubing; Zhang, Bin; Qin, Shukui 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI